Constantine J Karvellas1, Jaime L Speiser2, Mélanie Tremblay3, William M Lee4, Christopher F Rose3. 1. Division of Gastroenterology and Department of Critical Care Medicine, University of Alberta, Edmonton, Canada. 2. Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC. 3. Hepato-neuro Laboratory, CRCHUM, Université de Montréal, Montréal, Canada. 4. Division of Digestive and Liver Diseases, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Abstract
Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver-type fatty acid binding protein (FABP1) early (day 1) or late (day 3-5) levels are associated with 21-day mortality in the absence of liver transplant. Serum samples from 198 APAP-ALF patients (nested case-control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme-linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014). APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P < 0.0001) and late (148.4 versus 612.3 ng/mL, P < 0.0001) compared with nonsurvivors. FABP1 > 350 ng/mL was associated with significantly higher risk of death at early (P = 0.0004) and late (P < 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio = 1.31, P = 0.027) and late (log FABP1 odds ratio = 1.50, P = 0.005) were associated with significantly increased 21-day mortality after adjusting for significant covariates (Model for End-Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (P < 0.002 for all). CONCLUSION: In patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation. (Hepatology 2017;65:938-949).
Acetaminophen (APAP)-induced acute liver failure (ALF) is associated with significant mortality. Traditional prognostic scores lack sensitivity. Serum liver-type fatty acid binding protein (FABP1) early (day 1) or late (day 3-5) levels are associated with 21-day mortality in the absence of liver transplant. Serum samples from 198 APAP-ALFpatients (nested case-control study with 99 survivors, 99 nonsurvivors) were analyzed by enzyme-linked immunosorbent assay with clinical data from the US Acute Liver Failure Study Group registry (1998-2014). APAP-ALF survivors had significantly lower serum FABP1 levels early (238.6 versus 690.8 ng/mL, P < 0.0001) and late (148.4 versus 612.3 ng/mL, P < 0.0001) compared with nonsurvivors. FABP1 > 350 ng/mL was associated with significantly higher risk of death at early (P = 0.0004) and late (P < 0.0001) time points. Increased serum FABP1 early (log FABP1 odds ratio = 1.31, P = 0.027) and late (log FABP1 odds ratio = 1.50, P = 0.005) were associated with significantly increased 21-day mortality after adjusting for significant covariates (Model for End-Stage Liver Disease, vasopressor use). Areas under the receiver operating characteristic curve for early and late multivariable models were 0.778 and 0.907, respectively. The area under the receiver operating characteristic curve of the King's College criteria (early, 0.552 alone, 0.711 with FABP1; late, 0.604 alone, 0.797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766 with FABP1; late, 0.711 alone, 0.815 with FABP1) significantly improved with the addition of FABP1 (P < 0.002 for all). CONCLUSION: In patients with APAP-ALF, FABP1 may have good potential to discriminate survivors from nonsurvivors and may improve models currently used in clinical practice; validation of FABP1 as a clinical prediction tool in APAP-ALF warrants further investigation. (Hepatology 2017;65:938-949).
Authors: Maartje A J van den Broek; Johanne G Bloemen; Simon A W G Dello; Marcel C G van de Poll; Steven W M Olde Damink; Cornelis H C Dejong Journal: J Hepatol Date: 2010-12-13 Impact factor: 25.083
Authors: Anne M Larson; Julie Polson; Robert J Fontana; Timothy J Davern; Ezmina Lalani; Linda S Hynan; Joan S Reisch; Frank V Schiødt; George Ostapowicz; A Obaid Shakil; William M Lee Journal: Hepatology Date: 2005-12 Impact factor: 17.425
Authors: P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim Journal: Hepatology Date: 2001-02 Impact factor: 17.425
Authors: Adrian Reuben; Holly Tillman; Robert J Fontana; Timothy Davern; Brendan McGuire; R Todd Stravitz; Valerie Durkalski; Anne M Larson; Iris Liou; Oren Fix; Michael Schilsky; Timothy McCashland; J Eileen Hay; Natalie Murray; Obaid S Shaikh; Daniel Ganger; Atif Zaman; Steven B Han; Raymond T Chung; Alastair Smith; Robert Brown; Jeffrey Crippin; M Edwyn Harrison; David Koch; Santiago Munoz; K Rajender Reddy; Lorenzo Rossaro; Raj Satyanarayana; Tarek Hassanein; A James Hanje; Jody Olson; Ram Subramanian; Constantine Karvellas; Bilal Hameed; Averell H Sherker; Patricia Robuck; William M Lee Journal: Ann Intern Med Date: 2016-04-05 Impact factor: 25.391
Authors: Maria Mikus; Kimi Drobin; Marcus Gry; Julie Bachmann; Johan Lindberg; Getnet Yimer; Eleni Aklillu; Eyasu Makonnen; Getachew Aderaye; James Roach; Ian Fier; Caroline Kampf; Jens Göpfert; Hugo Perazzo; Thierry Poynard; Camilla Stephens; Raúl J Andrade; M Isabel Lucena; Nadir Arber; Mathias Uhlén; Paul B Watkins; Jochen M Schwenk; Peter Nilsson; Ina Schuppe-Koistinen Journal: Liver Int Date: 2016-06-22 Impact factor: 5.828
Authors: Joel H Vazquez; Stefanie Kennon-McGill; Stephanie D Byrum; Samuel G Mackintosh; Hartmut Jaeschke; D Keith Williams; William M Lee; Jonathan A Dranoff; Mitchell R McGill Journal: Toxicol Sci Date: 2022-04-26 Impact factor: 4.109
Authors: Constantine J Karvellas; Jaime L Speiser; Mélanie Tremblay; William M Lee; Christopher F Rose Journal: Ann Intensive Care Date: 2017-10-05 Impact factor: 6.925